SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company, today announced the appointment of Faheem Hasnain as an independent director of the company. The appointment of Mr. Hasnain fills the vacancy in Class II of the company’s board of directors, which class is serving a term that expires at the company’s annual meeting of stockholders in 2013. The number of company directors stands at eight, with a five-member independent majority.
